Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash & Current Investments (2022 - 2025)

Historic Cash & Current Investments for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $13.7 million.

  • Atara Biotherapeutics' Cash & Current Investments fell 7959.19% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 7959.19%. This contributed to the annual value of $42.5 million for FY2024, which is 1784.24% down from last year.
  • Atara Biotherapeutics' Cash & Current Investments amounted to $13.7 million in Q3 2025, which was down 7959.19% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Cash & Current Investments ranged from a high of $331.3 million in Q2 2022 and a low of $13.7 million during Q3 2025
  • Its 4-year average for Cash & Current Investments is $126.4 million, with a median of $67.2 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 1784.24% in 2024, then plummeted by 7959.19% in 2025.
  • Atara Biotherapeutics' Cash & Current Investments (Quarter) stood at $242.8 million in 2022, then plummeted by 78.7% to $51.7 million in 2023, then decreased by 17.84% to $42.5 million in 2024, then tumbled by 67.73% to $13.7 million in 2025.
  • Its Cash & Current Investments was $13.7 million in Q3 2025, compared to $22.3 million in Q2 2025 and $14.0 million in Q1 2025.